These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24747911)

  • 1. Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
    Schoumacher M; Hurov KE; Lehár J; Yan-Neale Y; Mishina Y; Sonkin D; Korn JM; Flemming D; Jones MD; Antonakos B; Cooke VG; Steiger J; Ledell J; Stump MD; Sellers WR; Danial NN; Shao W
    Cancer Res; 2014 Jun; 74(12):3294-305. PubMed ID: 24747911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
    Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
    Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
    Sun C; Hobor S; Bertotti A; Zecchin D; Huang S; Galimi F; Cottino F; Prahallad A; Grernrum W; Tzani A; Schlicker A; Wessels LF; Smit EF; Thunnissen E; Halonen P; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Trusolino L; Bernards R
    Cell Rep; 2014 Apr; 7(1):86-93. PubMed ID: 24685132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
    Van Schaeybroeck S; Kalimutho M; Dunne PD; Carson R; Allen W; Jithesh PV; Redmond KL; Sasazuki T; Shirasawa S; Blayney J; Michieli P; Fenning C; Lenz HJ; Lawler M; Longley DB; Johnston PG
    Cell Rep; 2014 Jun; 7(6):1940-55. PubMed ID: 24931611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
    Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
    Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
    Moon JH; Hong SW; Kim JE; Shin JS; Kim JS; Jung SA; Ha SH; Lee S; Kim J; Lee DH; Park YS; Kim DM; Park SS; Hong JK; Kim DY; Kim EH; Jung J; Kim MJ; Kim SM; Deming DA; Kim K; Kim TW; Jin DH
    Br J Cancer; 2019 Apr; 120(9):941-951. PubMed ID: 30944457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
    J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
    Okumura S; Jänne PA
    Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
    Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.